What Is SS-31?
$103.95 · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA
Comprar peptídeo SS-31 50mg (Elamipretide)Resposta Rapida
Visao Geral SS-31 (elamipretide) e um(a) sintetico(a), aromatic-cationic tetrapeptide pertencente a the Szeto-Schiller (SS) family of mitochondria-targeted peptides. Its sequence — D-Arg-Dmt-Lys-Phe-NH₂ — alternates cationic residues (D-Arg, Lys) with aromatic residues (Dmt, Phe), an architectural p...
SS-31 — Quick Facts
| Molecular formula | C32H49N9O5 |
|---|---|
| Molecular weight | 639.8 g/mol |
| InChI key | SFVLTCAESLKEHH-WKAQUBQDSA-N |
| PubChem CID | 11764719 |
| Storage | Pó liofilizado de grau de pesquisa. Armazene a -20 °C ou menos, dessecado, protegido da luz. |
| Cited references | 17 |
Chemical identity from PubChem CID 11764719. For research use only.
Visao Geral
SS-31 (elamipretide) e um(a) sintetico(a), aromatic-cationic tetrapeptide pertencente a the Szeto-Schiller (SS) family of mitochondria-targeted peptides. Its sequence — D-Arg-Dmt-Lys-Phe-NH₂ — alternates cationic residues (D-Arg, Lys) with aromatic residues (Dmt, Phe), an architectural pattern que confere selective, high-affinity binding to cardiolipin (CL) no(a) inner membrana mitocondrial (IMM).[1][2]
Discovery: SS-31 was identificado(a) serendipitously by Dr. Hazel Szeto (Weill Cornell Medical College) and Dr. Peter Schiller (Montreal IRCM) during research into opioid agonista do receptors. It was derivado(a) de SS-02 ([Dmt¹]DALDA), a synthetic opioid peptide analog, but projetado(a) para completely eliminate opioid receptor activity enquanto retaining the aromatic-cationic motif necessario(a) para mitochondrial targeting.[1]
Key distinguishing features: (1) Concentrates 5,000-fold no(a) IMM via cardiolipin binding; (2) Uptake is membrane-potential-independent (diferentemente de MitoQ, que requer intact electrochemical gradient); (3) Has no effect on healthy mitochondria; (4) Small, water-soluble, crosses the blood-brain barrier.[2][4]
Regulatory milestone: On September 19, 2025, the FDA granted Accelerated Approval to Forzinity™ (elamipretide) for Barth syndrome — a rare genetic disorder caused by TAFAZZIN gene mutations levando a cardiolipin deficiency. This made SS-31 the first drug ever authorized pelo(a) FDA specifically for Barth syndrome, and one do(a) primeiro(a) mitochondrially-targeted drugs to receive aprovacao da FDA for qualquer indication.[3]
Comparado(a) a MOTS-c — another mitochondria-targeted composto de pesquisa — SS-31 acts upstream at o nivel of cardiolipin e o(a) electron transport chain itself, rather do que via nuclear gene regulacao.[1]
“Preclinical & Clinical Research Summary Key Preclinical Studies EstudoModeloPrincipais AchadosRef Sabbah et al.”
Referencias
- Szeto HH. British Journal of Pharmacology. 2014;171(8):2029-2050.
- Birk AV, Liu S, Soong Y, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. Journal do(a) American Society of Nephrology. 2013;24(8):1250-1261.
- FDA Press Announcement. September 19, 2025.
- Campbell MD, Duan J, Bhatt SK, et al. Free Radical Biology and Medicine. 2019;134:268-281.
- Sabbah HN. Elamipretide (SS-31) melhora funcao mitocondrial and previne cellular apoptose in insuficiencia cardiaca e seu(sua) comorbidities. Expert Opinion on Investigational Drugs. 2021;30(12):1227-1244.
- Sabbah HN, Gupta RC, Kohli S, et al. Circulation: Heart Failure. 2016;9(2):e002206.
- Sabbah HN, Klewer SE, O'Brien T, et al. Elamipretide and NF-κB/NLRP3 inflammasome inibicao. Biomedicine & Pharmacotherapy. 2025;183:118056.
- Zhao W, Xu Z, Cao J, et al. Scientific Reports. 2019;9(1):13137.
- Thompson WR, Hornby B, Manuel R, et al. Genetics in Medicine. 2024;101138.
- Karaa A, Haas R, Goldstein A, et al. Neurology. 2018;90(14):e1212-e1221.
- Birk AV, Chao WM, Bracken C, et al. Targeting mitochondrial cardiolipin e o(a) cytochrome c/cardiolipin complex para promover electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014;171(8):2017-2028.
- Cousins D, Brar P, McFarlane T, et al. Ophthalmology Retina. 2023.
- Saad A, Herrmann SMS, Eirin A, et al. Circulation: Cardiovascular Interventions. 2017;10(9):e005130.
- Dai DF, Hsieh EJ, Chen T, et al. Global proteomics and pathway analysis of pressure-overload-induziu insuficiencia cardiaca e seu(sua) attenuation by mitochondrial-targeted peptides. Circulation: Heart Failure. 2013;6(5):1067-1076.
- Chiao YA, Rabinovitch PS, Bhatt SK, et al. eLife. 2020;9:e55513.
- Lincoff AM, Bhatt DL, Fischell T, et al. Elamipretide and post–cardiac arrest outcomes (EMBRACE STEMI). American Heart Journal. 2014;168(2):222-228.
- Cited source. 2025.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Comprar peptídeo SS-31 50mg (Elamipretide)→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.
